Adverum Biotechnologies - מכפיל מחיר להכנסות עתידי ADVM
The stable management of Adverum Biotechnologies (ADVM) has established the foundation for the final stages of trials, which supports the issuer's forward P/S. The company aims to capture the ocular gene therapy niche through its Ixo-vec drug. The prospect of replacing frequent injections for AMD with a single shot makes the asset an attractive M&A target, and 90.80 becomes the new metric value determining the business's market valuation.
פילוחי מדדים ואנליטיקה של חברת Adverum Biotechnologies Inc. (ADVM)
Forward P/S measures the market value of a business relative to its expected sales volume, allowing investors to assess the degree of optimism priced in between reporting periods. By analyzing the expected P/S multiple, one can evaluate the extent to which the market has priced the success of Adverum Biotechnologies (ADVM) gene therapy clinical expansion and the completion of Phase II/III trials into the company's current capitalization.
